about
Stable isotope-resolved metabolomics and applications for drug developmentDirect Optofluidic Measurement of the Lipid Permeability of Fluoroquinolones.High resolution crystal structures of Mycobacterium tuberculosis adenosine kinase: insights into the mechanism and specificity of this novel prokaryotic enzymeExhaustive Fluorine Scanning toward Potent p53-Mdm2 AntagonistsDevelopment of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission TomographyChromosomal aneuploidies and DNA fragmentation of human spermatozoa from patients exposed to perfluorinated compoundsThe HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase functionPotential of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinones against Leishmania (L.) infantum: biological activity and structure-activity relationshipsThe synthesis of a geminally perfluoro-tert-butylated beta-amino acid and its protected forms as a potential pharmacokinetic modulator and reporter for peptide-based pharmaceuticalsMemory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease.The challenges of in silico contributions to drug metabolism in lead optimization.Radiochemistry on electrodes: Synthesis of an 18F-labelled and in vivo stable COX-2 inhibitor.Biosynthesis of Fluorinated Peptaibols Using a Site-Directed Building Block Incorporation Approach.Natural and engineered biosynthesis of fluorinated natural products.Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic propertiesThe role of fluorine in medicinal chemistry.Chemo-enzymatic fluorination of unactivated organic compounds.P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.Understanding Solvent Effects in the Solvolyses of 4-Fluorophenyl Chlorothionoformate.Design of gem-difluoro-bis-tetrahydrofuran as P2 ligand for HIV-1 protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation.Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved PharmacokineticsThe polar hydrophobicity of fluorinated compounds.Fluorine in medicinal chemistry.The coordination chemistry of fluorine in fluorocarbons.Spectro-Fluor™ Technology for Reliable Detection of Proteins and Biomarkers of Disease: A Pioneered Research Study.Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activitiesFluoride-containing podophyllum derivatives exhibit antitumor activities through enhancing mitochondrial apoptosis pathway by increasing the expression of caspase-9 in HeLa cells.Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitorsSynthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.Comprehensive structural studies of 2',3'-difluorinated nucleosides: comparison of theory, solution, and solid state.Voriconazole-induced periostitis in a patient with overlap syndromesSynthesis and SAR studies of dual AKT/NF-κB inhibitors against melanoma.The role and future potential of fluorinated biomarkers in positron emission tomography.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).19F NMR: a valuable tool for studying biological events.Boron-(18) F containing positron emission tomography radiotracers: advances and opportunities.Recent advances in fluorination techniques and their anticipated impact on drug metabolism and toxicity.Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.Synthesis, molecular structure and spectroscopic investigations of novel fluorinated spiro heterocycles.
P2860
Q24629149-DAEB68E6-E7F8-44CA-AAF2-D6EE13F806E4Q27312442-01AA4173-C054-4F60-BD14-3A5CB9DD0111Q27646464-087604D8-1346-4B55-B3DD-9E6A6F5B3A3CQ27674554-2A096A6C-F9E3-4E53-831B-AC29DFD9067FQ27679693-FC70C2E6-E834-41E1-8212-719D62BF9F8AQ28251251-E4A9195B-DE3E-4539-8597-F536E2CFEB8EQ28480396-85185E12-3012-4C09-B520-855E297AB47AQ28542652-34C28F67-426A-4483-A80F-EE95770DE6F0Q31095502-790AAEB4-2DC9-49AB-9924-F4E9238AC7FCQ33556959-65686AB9-2696-4C63-B2D5-A5B2B091DEF3Q33610567-C689F0E2-FAC0-4C40-B50C-424EF8D8CF01Q33626578-87A7EEF0-608C-4539-BBA2-98D09A9044DDQ33836344-763BE5AD-30E9-4BDC-A88F-FEFB158A6C1EQ34417583-780606AC-06A1-49B5-BF3A-472299651AE7Q34602618-3A3EF310-D761-4FD0-BF40-6D6244DE0565Q34717922-35E11174-A89B-4790-AD57-6C7B1DEA38B5Q34881340-BDB48B38-7FF5-4DE3-9D88-3651B9731B30Q35057007-864C25CC-9073-4C73-B546-CAAC59CB4009Q35212157-3F6DABD8-B05A-4399-B311-FB1D932C683CQ35569236-870028C5-5BEC-4432-848A-7B70FF6355ECQ35598226-0FB61DB8-72B5-48C3-92D4-5F9EA472B3BAQ35762540-6ABFCE62-97E7-4B18-B78C-7AA8AC59743FQ35762548-42C36B87-F5C2-40F1-91AF-FA2458F81882Q35762557-1C261546-B84A-427F-8DC8-12F915B19DCFQ35916792-00146DDB-13EA-4C9C-BB55-2CD8E03953C3Q36142192-F7D7250D-180C-48CA-9240-8476A06245DDQ36320965-2D9B4AF7-9B02-435B-9BF8-C2F14771BA2EQ36709236-9468A9D0-19EF-428B-9497-70C2324147A9Q36958767-F1837A3B-7F00-4072-AC78-E57033559CDCQ36984451-E5032417-3F35-4803-9512-CAF45ED1A8C1Q37336619-E9310832-3094-4613-A284-F16F0EBDE379Q37627809-5174023F-0EA1-4165-943F-699A96868D40Q37664921-133FFFAE-D941-43B5-8910-E77FFCF9E832Q38028536-1CA24583-F41B-4EE6-A6AA-3AB14E0C7CCCQ38101883-609E0C1E-D49A-4ABF-AB3A-C7D4D9A5F608Q38122313-C086EA32-D604-4AB3-B357-55C4EAF23170Q38237969-3B7A5CB9-C55B-4D4C-9FAE-65A108CC856EQ38366495-98CD7EEA-4AE3-4179-B6FB-C406103164F7Q38418951-F4D4B638-54BA-450A-94DF-ABAEF07E05FFQ38547108-4C7A3D5C-E444-4FD2-BA0B-D0E68DB11ABC
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Metabolism of fluorine-containing drugs.
@ast
Metabolism of fluorine-containing drugs.
@en
Metabolism of fluorine-containing drugs.
@nl
type
label
Metabolism of fluorine-containing drugs.
@ast
Metabolism of fluorine-containing drugs.
@en
Metabolism of fluorine-containing drugs.
@nl
prefLabel
Metabolism of fluorine-containing drugs.
@ast
Metabolism of fluorine-containing drugs.
@en
Metabolism of fluorine-containing drugs.
@nl
P2093
P1476
Metabolism of fluorine-containing drugs.
@en
P2093
Kitteringham NR
O'Neill PM
P304
P356
10.1146/ANNUREV.PHARMTOX.41.1.443
P577
2001-01-01T00:00:00Z